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Extra-Fine Particles Improve Lung
Delivery of Inhaled Steroids in Infants*
A Study in an Upper Airway Model
Hettie M. Janssens, MD, PhD; Johan C. de Jongste, MD, PhD;
Wim C. J. Hop, MD, PhD; and Harm A. W. M. Tiddens, MD, PhD
Background: The particles of a new hydrofluoroalkane-134a (HFA)-beclomethasone dipropionate
(BDP) metered-dose inhaler (Qvar; 3M Pharmaceuticals; St. Paul, MN) are considerably smaller
than those of chlorofluorocarbon (CFC)-BDP. This may improve lung deposition in infants who
inhale nasally and have irregular breathing patterns and small airways.
Aim: To compare the dose delivered to the lungs of HFA-BDP and CFC-BDP at different
breathing patterns using an upper airway model of an infant.
Methods: An anatomically correct upper airway model of a 9-month-old child with an open nasal
airway was connected to an impactor and breathing simulator. HFA-BDP, 100 g, and CFC-BDP,
100 g, were delivered to the model through a detergent-coated, small-volume spacer. The total
dose leaving the model (lung dose), its particle size distribution, and median mass aerodynamic
diameter (MMAD) were assessed during simulated tidal breathing with tidal volumes (VTs) of
50 mL, 100 mL, and 200 mL, and 30 breaths/min. Dose was expressed as percentage of nominal
dose.
Results: Lung doses for HFA-BDP were 25.4%, 26.5%, and 30.7% compared with 6.8%, 4.8%, and
2.1% for CFC-BDP at VTs of 50 mL, 100 mL, and 200 mL, respectively. The dose of particles
< 2.1 m to the lung for HFA-BDP was 23 to 28% compared with 0.6 to 0.8% for CFC-BDP. The
lung dose of CFC-BDP mainly consisted of particles between 2.1 m and 4.7 m. MMAD for
HFA-BDP was 1.2 m, and 2.6 to 3.3 m for CFC-BDP depending on VT. The lung dose for
CFC-BDP decreased significantly with increasing VT. HFA-BDP lung dose did not alter
significantly with VT.
Conclusions: In this infant model study, the use of HFA-BDP with a high dose of particles
< 2.1 m improves the dose delivered to the lungs substantially. Furthermore, the large
proportion of extra-fine particles in HFA-BDP results in lung doses less dependent on breathing
pattern compared with CFC-BDP. (CHEST 2003; 123:2083–2088)
Key words: aerosol deposition; airway model; beclomethasone; hydrofluoroalkane; infants; metered-dose inhalers
Abbreviations: BDP  beclomethasone dipropionate; CFC chlorofluorocarbon; EFPD extra-fine particle dose;
FPD  fine particle dose; HFA hydrofluoroalkane-134a; MMAD median mass aerodynamic diameter;
pMDI  pressurized metered-dose inhaler; SAINT Sophia Anatomical Infant Nose-Throat; Vt  tidal volume
I nhaled steroids have been shown to reduce symp-toms in infants with wheezing.1 A convenient way
to administer inhaled steroids to the lungs of infants
is by a pressurized metered-dose inhaler (pMDI)
combined with spacer and attached face mask2;
however,1 only a small proportion of the adminis-
tered dose is deposited in the lungs of young chil-
dren,3,4 and the inhaled dose is highly variable.5 The
replacement of chlorofluorocarbons (CFCs) by
ozone-friendly propellants, such as hydrofluoroal-
kane-134a (HFA), has been an opportunity to revise
the delivery properties of pMDIs.6 The new HFA-
beclomethasone dipropionate (BDP) [Qvar; 3M
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Pharmaceuticals; St. Paul, MN] has a large propor-
tion of small particles compared with conventional
formulations. This has been shown to result in a
higher and a more peripheral lung deposition in
adults.7 There are reasons to believe that these small
particles may also be beneficial for treatment of
infants. Firstly, infants inhale aerosols mainly na-
sally.8 Small particles are more likely to bypass the
nose and to be deposited in the lungs compared with
larger particles.9 Secondly, infants may not cooperate
during the administration procedure, leading to cry-
ing or irregular and fast breathing while inhaling the
aerosol. Crying and high inspiratory flow rates have
been shown to result in decreased lung deposi-
tion,4,10 with only small particles reaching the
lungs.11 Thirdly, the narrow airways of infants are
characterized by high-velocity and turbulent airflow
causing increased deposition of particles in the prox-
imal airways.12,13 Small particles are more likely to
reach the peripheral airways.14 Dose delivered to the
lungs of the new HFA-BDP has not yet been studied
in infants. Lung deposition studies in infants using
radiolabeled aerosols are difficult to perform and
subject to ethical discussion.15 To facilitate aerosol
research in relation to young children, we recently
developed an anatomically correct model of the
upper airways of an infant.16 The dose passing
through this model, which includes the face, nasal
cavity, and larynx the subglottic region, was shown to
compare well with available in vivo lung deposition
data.4,11,17,18 We hypothesized that HFA-BDP would
deliver a substantially higher dose to the lungs with
less dependence on breathing pattern or inspiratory
flow rate, compared with CFC-BDP.
Materials and Methods
Upper Airway Model
A model of the upper airways of an infant was used for the
aerosol deposition measurements. This model, the Sophia Ana-
tomical Infant Nose-Throat (SAINT) model, was extensively
described elsewhere.16 In short, the SAINT model is a CT
scan-derived, stereolithographically made, anatomically correct
model of the upper airways of a 9-month-old infant. The model
includes the face, nasal cavity, and pharynx to the subglottic
region. The nasal airway is open for air passage; the oral airway is
closed. To mimic sticky mucosa and to eliminate any electrostatic
charge present on the inner surface of the model, the inner
surface of the model is coated with a thin layer of glycerol/Brij-35
(polyoxyethylene 23 laurylether) mixture by pipetting 4 mL into
the model and allowing the excess fluid to drip out.
pMDI/Spacer
Two pMDIs containing BDP were tested. HFA-BDP (Qvar)
was compared with CFC-BDP (Becotide; GlaxoWellcome; Ux-
bridge, UK). Before testing, the pMDIs were primed by shaking
and firing 10 waste puffs. The pMDIs were used in combination
with a small-volume plastic spacer (Aerochamber; Trudell Med-
ical; London, Canada). The spacer was used with the infant
facemask as provided by the manufacturer. Electrostatic charge
can develop on the inner surface of a plastic spacer, which
decreases drug delivery by retaining the drug in the spacer.19 To
reduce the electrostatic charge of the spacer, it was coated with
household detergent. Several hours before use, the spacer was
washed in diluted detergent and subsequently left to drip dry.
Detergent coating has been shown to reduce electrostatic charge
on the inner surface of the spacer.20,21
Experimental Set-up
The SAINT model was connected to a breathing simulator
(Pari Sinus Breathing Simulator; Pari GmbH; Starnberg, Ger-
many) and an Andersen 8-stage cascade impactor (Graseby
Andersen; Smyrna, GA) by means of a three-way glass connection
(Fig 1). A constant flow of 28.3 L/min through the impactor was
balanced with an inflow of 28.3 L/min through the glass connec-
tion, resulting in zero flow through the model. When the
breathing simulator was switched on, there was simulated tidal
breathing through the model and a constant flow through the
impactor. This set-up has been previously described and vali-
dated.22,23 Lung dose was defined as the total dose leaving the
SAINT model, expressed as a percentage of nominal dose. Fine
particle dose (FPD) was defined as the mass of the lung dose in
particles  4.7 m (impactor stage 3 to 8) expressed as a
percentage of nominal dose. Extra-fine particle dose (EFPD) was
defined as the mass of the lung dose in particles  2.1 m
(impactor stage 5 to 8) expressed as a percentage of nominal
dose. Particle size of lung dose was expressed as median mass
aerodynamic diameter (MMAD).
Breathing Simulation
Aerosol delivery was tested at various tidal volumes (Vts) using
sinusoidal tidal breathing patterns with the following settings for
the breathing simulator: respiratory duty cycle (inspiratory time/
total respiratory cycle time) of 0.42, and Vts of 50 mL, 100 mL,
and 200 mL with fixed respiratory rate of 30 breaths/min. A
respiratory duty cycle of 0.42, Vt of 100 mL, and respiratory rate
of 30 breaths/min are in accordance with reference values
appropriate for the age of the subject used to construct the
model.24 Measurements for each Vt were done three times in a
randomized order.
Study Procedure
The SAINT model was attached to the clean impactor, and the
breathing simulator was started. The pMDI/spacer with facemask
was shaken and placed on the face of the model, ensuring an
airtight fit using therapeutic putty (Carters; Westbury, UK).
Within 5 s of being shaken, one puff of HFA-BDP or CFC-BDP
was actuated into the spacer just before the start of an inspiration.
Aerosol was drawn from the spacer during 30 s of simulated tidal
breathing. Ten separate puffs were actuated for each impactor
measurement to get detectable amounts of drug on the impactor
plates. The experiments were performed in ambient conditions
with 30 to 40% humidity.
Drug Analysis
Drug on the impactor plates and glass connection was dis-
solved in ethanol containing an internal standard (fluocinolone
acetonide). BDP was quantified using a validated high-perfor-
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mance liquid chromatography method, comprising an ethanol:
water (43:57) mobile phase and a Supelcosil LC-18 column
(5 m particles; 5  0.46-cm inner diameter). The coefficient of
variation of the method was  3%.
Statistical Analysis
The amount of BDP found is expressed as a percentage of
nominal dose. Results shown are means ( SEM). Comparisons
between dose delivery from HFA-BDP and CFC-BDP were
tested using an independent-sample t test for each Vt. The
following variables were tested: lung dose, FPD, EFPD, and
MMAD. The correlations between Vt and these variables were
investigated using Pearson correlation coefficients. Analysis of
covariance was used to show differences between the relation-
ships of HFA-BDP and CFC-BDP deposition variables with Vt.
Statistical significance was set at p 0.05.
Results
Results for lung dose are shown in Figure 2A.
Lung doses for HFA-BDP were 25.4% (2.0), 26.5%
(3.6), and 30.7% (0.5) compared with 6.8% (1.1),
4.8% (0.7), and 2.1% (0.1) for CFC-BDP at Vts of
50 mL, 100 mL, and 200 mL, respectively. The
differences between HFA-BDP and CFC-BDP
were highly significant (p 0.001) for all Vts. Fur-
thermore, the lung dose of HFA-BDP did not
significantly depend on Vt, whereas lung dose of
CFC-BDP showed a significant decrease with in-
creasing Vt.
Results for FPD (particles 4.7 m) are shown in
Figure 2B. FPDs for HFA-BDP lung dose were
24.1% (1.9), 24.5% (2.7), and 28.7% (0.5) compared
with 5.8% (1.0), 4.4% (0.6), and 1.9% (0.1) for
CFC-BDP at Vts of 50 mL, 100 mL, and 200 mL,
respectively. The differences between HFA-BDP
and CFC-BDP were highly significant for all Vts
(p  0.001). Furthermore, FPD of HFA-BDP did
not significantly depend on Vt, whereas FPD of
CFC-BDP showed a significant decrease with in-
creasing Vt.
Results for EFPD (particles  2.1 m) are shown
in Figure 2C. EFPDs for HFA-BDP lung dose were
23.6% (1.9), 23.5% (3.1), and 28.3% (0.5) compared
with 0.8% (0.2), 0.6% (0.3), and 0.6% (0.1) of
CFC-BDP at Vts of 50 mL, 100 mL, and 200 mL,
respectively. The differences between HFA-BDP
and CFC-BDP were highly significant (p 0.001).
EFPD of HFA-BDP and of CFC-BDP showed no
significant correlation with Vt.
Results for MMAD of lung dose are shown in
Figure 1. Experimental set-up used to measure lung dose and particle size from pMDI/spacer during
simulated tidal breathing. The breathing simulator supplied tidal breathing through the SAINT model
and pMDI/spacer with a constant flow of 28.3 L/min through the impactor (Fai), balanced by an inflow
(Fi) of 28.3 L/min. A three-way glass connection attached all the parts together.
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Figure 2D. MMADs of HFA-BDP were 1.3 m
(0.03), 1.1 m (0.1), and 1.1 m (0.05) compared
with 3.3 m (0.01), 3.1 m (0.05), and 2.6 m (0.02)
of CFC-BDP at Vts of 50 mL, 100 mL, and 200 mL,
respectively. The differences between HFA-BDP
and CFC-BDP were highly significant (p 0.001).
MMAD of CFC-BDP showed a significant decline
with increasing Vt, whereas this decline was small
and borderline significant for the HFA-BDP.
Calculations of the separate regression lines for
both HFA-BDP and CFC-BDP showed that the
slopes were significantly different (p 0.008), for
lung dose, FPD, and MMAD, but not for EFPD.
This means that the relationships with Vt signifi-
cantly differed between HFA-BDP and CFC-BDP
except for EFPD.
Discussion
We studied the relation between lung dose and
particle size for HFA-BDP and CFC-BDP delivered
by pMDIs with a spacer device at different Vts in an
anatomically correct upper airway model of an in-
fant. The lung dose of HFA-BDP was 3.5-fold to
almost 15-fold higher compared with CFC-BDP for
different Vts. Furthermore, the lung dose of HFA-
BDP was independent of Vt, whereas the lung dose
of CFC-BDP showed a significant decrease with
increasing Vt. The lung dose of HFA-BDP consisted
mainly of particles  2.1 m, whereas the lung dose
of CFC-BDP consisted mainly of particles between
4.7 m and 2.1 m.
Our study is in agreement with previous lung
deposition studies using radiolabeled aerosols in
adults, where lung deposition was up to 10-fold
higher with HFA-BDP pMDI compared with CFC-
BDP, when used without a spacer.7 The lung dose
found using the SAINT model of approximately 30%
for HFA-BDP is in line with a study25 measuring
lung deposition of radiolabeled HFA-BDP in chil-
dren. Lung deposition of 41%, 45%, and 54% of
metered dose was found for children 5 to 7 years old,
8 to 10 years old, and 11 to 14 years old, respectively,
when inhaling HFA-BDP via an Autohaler (3M
Pharmaceuticals).25 That we found a lower dose can
be explained first by the fact that we used a spacer,
and second by the younger age of the child used for
the model compared with the age of the children in
the deposition study. The older children inhaled with
a single breath via the mouth, whereas the model
inhaled through the nose during tidal breathing,
which is the usual situation for a 9-month-old child.
Infants preferably breathe through the nose,
whether the mouth is open or not, as shown in a
radiolabeling study by Chua et al.8 Inhalation
Figure 2. Comparison of aerosol deposition measurements in
SAINT model with HFA-BDP and CFC-BDP in relation to Vt.
Results are mean (SEM) of three measurements. A, Lung dose;
B, FPD ( 4.7 m); C, EFPD ( 2.1 m); D, MMAD.
p  0.001 for differences between HFA-BDP and CFC-BDP at
all Vts.
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through the nose reduces the amount of drug deliv-
ered to the lungs.8 In addition, with tidal breathing
some of the aerosol is lost with exhalation, as there is
no breath-holding. Furthermore, the expression of
lung deposition as a percentage of metered dose (or
ex-valve dose) is likely to result in a slightly higher
value than when expressed as a percentage of nom-
inal dose (or label claim). Studies testing radiola-
beled CFC-salbutamol pMDI (Ventolin; GlaxoWell-
come; Research Triangle Park, NC) used with an
Aerochamber found lung depositions of 0.67% for
preterm infants3 and 1.97% for children  5 years of
age.4 These deposition data are comparable with,
respectively, the EFPD and FPD found with the
CFC-BPD. Our results suggest that the HFA-BDP,
due to smaller particles, will give a considerable
higher lung dose in infants than CFC formulations
with the same spacer.
Although the lung doses found with our model
reasonably correspond with in vivo data, the data
should still be considered as in vitro data. The
aerosols were administered in optimal conditions,
with idealized breathing patterns. Additionally, dif-
ferences in upper airway geometry between children
are likely to result in different lung deposition for a
given pMDI/spacer combination. Therefore, the
data found with the model should be considered as
estimations of the in vivo situation. The relative
differences are more informative than the absolute
values.
Lung dose of HFA-BDP was not dependent on
Vt, whereas lung dose of CFC-BDP decreased
rapidly with increasing Vt. With increasing Vt, peak
inspiratory flow rate increases. It has been shown in
adults that fast inhalation leads to lower lung depo-
sition compared with slow inhalation.26 Flow will
have a turbulent pattern with high inspiratory flow
rate in the narrow upper airways. As a result, coarse
particles are more likely to deposit in the upper
airways by inertial impaction, and thus lung dose will
be lower. This appears not to be the case for the
EFPD of CFC-BDP and HFA-BDP, which is largely
independent of breathing pattern. Since 90% of the
lung dose of HFA-BDP consists of particles
 2.1 m, the lung dose is less dependent on
breathing pattern compared with CFC-BDP. Only
13% of the lung dose of CFC-BDP has particles
 2.1 m.
The lung dose in our model indicates the dose
delivered beyond the subglottic level. It does not
give information on the distribution of drug in the
lower airways; however, particle size gives an indica-
tion on where the aerosol may deposit, as it has been
shown in several theoretical and clinical aerosol
deposition models that small particles deposit more
peripherally in the airways than larger particles.27 A
lung deposition study7 in adults showed that the
distribution of HFA-BDP was more peripheral in
the lungs compared with CFC-BDP. The relation
between particle size and deposition pattern is not
known for infants. It is likely that the high EFPD of
the HFA-BDP will improve peripheral deposition in
infants.
The clinical consequences of the improved aerosol
characteristics might be considerable. A high lung
dose which is independent of breathing pattern may
be an advantage for children who are not cooperative
during the administration of aerosol. It has been
shown that crying reduces lung deposition from a
pMDI/spacer to almost zero.10 Almost 50% of young
children are not cooperative during the administra-
tion procedure.5 These children might benefit from
HFA-BDP for control of asthma symptoms. With the
increased lung dose in infants and potential for
improved lung distribution, it is expected that the
daily dose of HFA-BDP needed to control asthma
symptoms will be substantially reduced compared
with CFC-BDP. In adults with asthma, it was shown
that the dose of HFA-BDP could be reduced 2.6
times to obtain the same improvement in lung
function as with CFC-BDP.28 Clinical efficacy stud-
ies are needed to assess the lowest effective dose of
HFA-BDP in infants.
In conclusion, aerosol deposition tests using the
SAINT model and simulated breathing show that
HFA-BDP with a spacer gives substantially higher
lung doses than CFC-BDP with a spacer. Further-
more, the large proportion of EFPDs in HFA-BDP
results in lung doses less dependent on breathing
pattern compared with CFC-BDP. Further research
is needed to show that HFA-BDP improves treat-
ment efficacy in infants.
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